[The treatment of laryngeal movement disorders with botulinum toxin: part 2: experience and considerations].
Laryngeal dystonia (spasmodic dysphonia) is a movement disorder characterised by involuntary contractions of the laryngeal muscles involved in vocalisation. The introduction of botulinum toxin (BTX) in the treatment of laryngeal dystonia had a major clinical impact due to the striking improvement of symptoms. In general, BTX can be delivered by percutaneous injection or by the transoral route. The subcutaneous method is simple, but the effects of the transoral injection, applied through a curved device or by use of a flexible nasolaryngoscope with a working channel and visual control, might be more effective. However, for various reasons the transoral route does not work in every patient. We report our experiences using these different techniques for the monitoring of patients and their treatment with botulinum toxin in laryngeal movement disorders.
Schwemmle
C
C
Klinik und Poliklinik für Phoniatrie und Pädaudiologie, Medizinische Hochschule Hannover, Carl- Neuberg-Str. 1, 30625, Hannover, Deutschland. schwemmle.cornelia@mh-hannover.de
Ptok
M
M
D001905:Botulinum Toxins / Q000008:administration & dosage*; D002986:Clinical Trials as Topic / Q000639:trends; D049672:History, 19th Century; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007818:Laryngeal Diseases / Q000188:drug therapy* / Q000266:history; D009069:Movement Disorders / Q000188:drug therapy* / Q000266:history; D010818:Practice Patterns, Physicians' / Q000266:history / Q000639:trends; D016896:Treatment Outcome; D014832:Voice Disorders / Q000188:drug therapy* / Q000266:history
D001905:Botulinum Toxins